0
No votes yet
ONS Guidelines Article

Supplementary Material for ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity

ONF 2020, 1-83 DOI:
  1. Guideline panel conflict of interest disclosures
  2. PICO questions
  3. Evidence-to-Decision Frameworks
  • EGFR inhibitor rash prevention—oral antibiotics (doxycycline, tetracycline, minocycline) and usual care vs. usual care
  • EGFR inhibitor rash treatment—topical corticosteroids with oral antibiotics and usual care vs. usual care
  • Hand-foot skin reaction prevention—topical urea and topical corticosteroids vs. usual care
  • Hand-foot syndrome prevention—oral pyridoxine (vitamin B6) vs. no oral pyridoxine (vitamin B6)
  • Hand-foot syndrome prevention—cooling procedures vs. no cooling procedures
  • Chemotherapy-induced alopecia prevention—scalp cooling vs. no scalp cooling
  • Chemotherapy-induced alopecia prevention—minoxidil vs. usual care